Campbell & CO Investment Adviser LLC Acquires Shares of 5,295 Charles River Laboratories International, Inc. $CRL

Campbell & CO Investment Adviser LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 5,295 shares of the medical research company’s stock, valued at approximately $803,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its position in shares of Charles River Laboratories International by 407.0% during the first quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock worth $150,142,000 after purchasing an additional 800,762 shares during the last quarter. Allspring Global Investments Holdings LLC raised its stake in Charles River Laboratories International by 29.1% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company’s stock valued at $353,750,000 after buying an additional 516,521 shares in the last quarter. Royal Bank of Canada lifted its holdings in Charles River Laboratories International by 304.7% during the 1st quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock worth $94,484,000 after buying an additional 472,606 shares during the last quarter. Ameriprise Financial Inc. lifted its holdings in Charles River Laboratories International by 144.3% during the 1st quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock worth $82,007,000 after buying an additional 321,789 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Charles River Laboratories International by 5.1% in the 1st quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company’s stock worth $644,980,000 after acquiring an additional 208,586 shares in the last quarter. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $168.97 on Friday. The firm has a market capitalization of $8.32 billion, a PE ratio of -127.05, a P/E/G ratio of 4.83 and a beta of 1.53. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The firm has a 50-day moving average price of $168.69 and a 200 day moving average price of $156.66. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $208.10.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business’s revenue for the quarter was down .5% compared to the same quarter last year. During the same period in the prior year, the business posted $2.59 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. Baird R W upgraded Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th. Mizuho upped their target price on shares of Charles River Laboratories International from $155.00 to $174.00 and gave the stock a “neutral” rating in a research report on Friday, October 17th. Finally, Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and lifted their price target for the company from $142.00 to $195.00 in a report on Tuesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $188.29.

Insider Transactions at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president directly owned 24,116 shares in the company, valued at approximately $3,800,681.60. This trade represents a 3.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).